Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL — Stella

Home/Autoimmune Hemolytic Anemia/

View on ClinicalTrials.gov

Recruiting

Back to Autoimmune Hemolytic Anemia trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(3 sites)

Italy

Ematologia Osp Careggi, Florence

Ematologia Osp Maggiore della Carità, Novara

Ematologia Osp Molinette, Torino

Key details

Phase

Safety & dosing

Sponsor

Gruppo Italiano Malattie EMatologiche dell'Adulto

Enrollment target

~45 participants

Started

November 2023

Primary completion

May 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years and older

Last updated December 2023

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.